Cancer Pharmacotherapy: review on monoclonal antibodies
DOI:
https://doi.org/10.5281/zenodo.17353578Keywords:
Drug Therapy, Neoplasms, Antibodies, MonoclonalAbstract
Oncology has undergone remarkable advances, driven by the development of more effective and safer therapies. In this context, monoclonal antibodies (mAbs) emerge as a promising alternative to conventional approaches, such as chemotherapy and radiotherapy, which face significant limitations. Recognizing the relevance of this topic, this study seeks to deepen knowledge about mAbs, exploring their main characteristics, mechanisms of action, clinical applications, adverse effects and contraindications. To this end, an integrative literature review was conducted, based on articles from the BVS/MedLine, BVS/Lilacs and Pubmed platforms. The descriptors used were “Neoplasms”, “Monoclonal Antibodies” and “Pharmacological Treatment”, combined by the Boolean operator AND. The inclusion criteria were limited to works published between 2018 and 2024, in Portuguese, English and Spanish, excluding case reports, abstracts, editorials and duplicates. After screening and analysis, the final sample consisted of nine articles. Since their pioneering creation in 1975, mAbs have evolved significantly due to advances in genetic engineering, which have overcome the initial immunogenicity of mouse-derived antibodies. Currently, humanized and humanized versions are widely used to treat various diseases, including cancer. However, challenges remain. The high cost, therapeutic resistance and adverse effects still hinder the widespread adoption of mAbs. Genetic engineering continues to expand possibilities, promoting the development of more effective and personalized mAbs, consolidating them as protagonists in oncological therapy and in the treatment of other serious conditions.
References
ASSOCIAÇÃO MÉDICA BRASILEIRA. Medicamentos biológicos na prática médica / Organização AMB - Associação Médica Brasileira. Interfarma - Associação da Indústria Farmacêutica de Pesquisa. São Paulo: Interfarma, 2013.
BRUNETO, V. R. et al. Anticorpos monoclonais no tratamento oncológico: Revisão de Literatura para o atendimento ao paciente e manejo das reações infusionais. Archives of Health Sciences, v. 26, n. 3, p. 173–178, 2019. DOI: https://doi.org/10.17696/2318-3691.26.3.2019.1369.
BUSSEL, M. T. J.; BEIJNEN, J. H.; BRANDSMA, D. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. BMC Cancer. v. 19, n. 1, p. 519, 2019. DOI: https://doi.org/10.1186/s12885-019-5741-y.
CALVETTI, L. et al. The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. Expert Opinion on Biological Therapy, p. 1–12, 2015.
CORDEIRO, M. L. da S. et al. Anticorpos Monoclonais: Implicações Terapêuticas no Câncer. Revista Saúde & Ciência Online, v. 3, n. 3, p. 252-262, 2014. DOI: https://doi.org/10.35572/rsc.v3i3.329.
COSTA, A. S. da.; Aplicação dos Anticorpos Monoclonais na Biotecnologia. 2019. 28 p. Trabalho de Conclusão de Curso (Bacharel em Biomedicina) - Centro Universitário De Brasília – UNICEUB, Brasília, 2019. Disponível em: https://repositorio.uniceub.br/jspui/bitstream/prefix/13642/1/21302810.pdf.
COSTA, D. M. A.; Aplicações Terapêuticas dos Anticorpos Monoclonais. 2015. 74 p. Dissertação (Mestre em Ciências Farmacêuticas) - Instituto Superior De Ciências Da Saúde Egas Moniz, 2015.
GOMES, F.; SERRA-BELLVER, P.; LORIGAN, P.; The role of nivolumab in melanoma. Future Oncology, v. 14, n. 13, p. 1241–1252, 2018. DOI: https://doi.org/10.2217/fon-2017-0484.
KAVEH, S. et al. Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis. International Journal of Clinical Pharmacy. 2019. DOI: https://doi.org/10.1007/s11096-018-0754-1.
KÜMLER, I.; CHRISTIANSEN, O. G.; NIELSEN, D. L. A systematic review of Bevacizumab efficacy in breast cancer. Cancer Treatment Reviews, v. 40, n. 8, p. 960–973, 2014. DOI: https://doi.org/10.1016/j.ctrv.2014.05.006.
LARSEN, P. B.; KÜMLER, I.; NIELSEN, D. L. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. Cancer Treatment Reviews, v. 39, n. 7, p. 720–727. 2013. DOI: https://doi.org/10.1016/j.ctrv.2013.01.006.
LIU, Y. C. et al. Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer. Medicine (Baltimore). v. 98, n. 38, p. e17262, 2019. DOI: https://doi.org/10.1097/MD.0000000000017262.
MACEDO, M. J. P. B. de. Estratégias e Inovações Aplicadas ao Desenvolvimento de Anticorpos Monoclonais. 2018. 50 p. Trabalho de Conclusão do Curso (Curso de Farmácia-Bioquímica) - Faculdade de Ciências Farmacêuticas da Universidade de São Paulo, São Paulo, 2018.
PRZEPIORKA, D. et al. FDA Approval: Blinatumomab. Clinical Cancer Research, v. 21, n. 18, p. 4035–4039, 2015. DOI: https://doi.org/10.1158/1078-0432.CCR-15-0612.
SANTOS, R. V. dos et al. Aplicações terapêuticas dos anticorpos monoclonais. Revista brasileira de Alergia e Imunopatologia, v. 29, n. 2, p. 77-85, 2006. Disponível em: http://aaai-asbai.org.br/imageBank/pdf/v29n2a04.pdf.
SANTOS-NETO, J. F. et al. Technological Advancements in Monoclonal Antibodies. The Scientific World Journal, v. 2021, p. 19, 2021. DOI: https://doi.org/10.1155/2021/6663708.
WANG, T. S. et al. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. Indian Journal of Cancer, v. 51, n. 3, p. e95-e98, 2014. DOI: https://doi.org/10.4103/0019-509X.154084.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Journal of Social Issues and Health Sciences (JSIHS)
This work is licensed under a Creative Commons Attribution 4.0 International License.
